Sale!

CEBPA Full Gene Mutation Analysis

Original price was: $300.Current price is: $226.

-25%

The CEBPA Full Gene Mutation Analysis is a comprehensive genetic test that examines the entire CEBPA gene for mutations associated with acute myeloid leukemia (AML). This advanced diagnostic tool helps identify specific genetic alterations that can influence leukemia development, treatment response, and prognosis. By analyzing the complete gene sequence, the test provides crucial information for personalized treatment planning and risk assessment. The test is particularly valuable for individuals with suspected or confirmed AML, family history of blood disorders, or unexplained hematological abnormalities. Results are typically available within 5-6 days from peripheral blood samples. The test costs $226 USD (discounted from $300 USD) and offers significant benefits for early detection and targeted therapy planning.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

CEBPA Full Gene Mutation Analysis: Comprehensive Genetic Testing for Leukemia Risk Assessment

Understanding CEBPA Full Gene Mutation Analysis

The CEBPA Full Gene Mutation Analysis represents a cutting-edge genetic diagnostic tool designed to detect mutations within the CCAAT/enhancer-binding protein alpha (CEBPA) gene. This comprehensive analysis plays a crucial role in modern hematological medicine, particularly in the diagnosis and management of acute myeloid leukemia (AML). The CEBPA gene encodes a transcription factor essential for normal myeloid differentiation, and mutations in this gene have been strongly associated with specific subtypes of AML.

What Does the Test Measure and Detect?

This advanced genetic analysis utilizes Sanger Sequencing technology to examine the entire CEBPA gene for various types of mutations, including:

  • Point mutations affecting single nucleotides
  • Insertions and deletions within the gene sequence
  • Frameshift mutations disrupting protein function
  • Nonsense and missense mutations altering protein structure
  • Complex mutations affecting multiple gene regions

Who Should Consider CEBPA Mutation Testing?

This genetic analysis is particularly recommended for individuals experiencing:

  • Unexplained cytopenias or abnormal blood counts
  • Suspected or newly diagnosed acute myeloid leukemia
  • Family history of hematological malignancies
  • Recurrent infections or unexplained bruising
  • Fatigue and weakness without clear cause
  • Previous abnormal bone marrow findings
  • Monitoring treatment response in known AML cases

Clinical Indications and Symptoms

Patients presenting with symptoms suggestive of myeloid disorders, including persistent fatigue, recurrent infections, easy bruising, or unexplained weight loss, may benefit from CEBPA mutation analysis. The test is especially valuable for individuals with suspected AML who require comprehensive genetic profiling for accurate diagnosis and treatment planning.

Benefits of CEBPA Full Gene Mutation Analysis

Undergoing this comprehensive genetic analysis offers multiple significant advantages:

  • Accurate Diagnosis: Provides definitive identification of CEBPA mutations associated with specific AML subtypes
  • Prognostic Information: Helps determine disease prognosis and expected treatment outcomes
  • Personalized Treatment: Guides selection of targeted therapies based on genetic profile
  • Early Detection: Enables identification of genetic risk factors before clinical symptoms manifest
  • Family Risk Assessment: Provides insights into potential hereditary components of hematological disorders
  • Treatment Monitoring: Allows tracking of genetic changes during therapy

Understanding Your Test Results

Your CEBPA Full Gene Mutation Analysis results will be carefully interpreted by our team of genetic specialists:

  • Normal Results: No mutations detected in the CEBPA gene sequence
  • Pathogenic Mutations: Identified genetic alterations known to cause disease
  • Variants of Uncertain Significance: Genetic changes requiring further investigation
  • Benign Polymorphisms: Common genetic variations without clinical significance

Our genetic counselors will provide comprehensive explanations of your results and discuss their implications for your health management plan.

Test Information and Pricing

Test Component Details
Test Name CEBPA Full Gene Mutation Analysis
Regular Price $300 USD
Discount Price $226 USD
Turnaround Time 5-6 Days
Sample Type Peripheral Blood
Test Components EDTA Vacutainer (2ml)
Testing Method Sanger Sequencing

Pre-Test Instructions

The CEBPA Full Gene Mutation Analysis requires a doctor’s prescription for testing. Please note that prescriptions are not applicable for surgical procedures, pregnancy cases, or individuals planning international travel. Our team will guide you through the sample collection process and ensure proper handling of your genetic material.

Nationwide Testing Availability

We proudly offer CEBPA Full Gene Mutation Analysis testing services across the United States, with convenient locations in major metropolitan areas including:

  • New York City and surrounding areas
  • Los Angeles and Southern California
  • Chicago and the Midwest region
  • Houston and Texas locations
  • Miami and Florida centers
  • Seattle and Pacific Northwest facilities
  • Boston and New England areas
  • Atlanta and Southeastern locations

Take Action for Your Genetic Health

Don’t wait to gain crucial insights into your genetic health. The CEBPA Full Gene Mutation Analysis provides valuable information that can significantly impact your healthcare journey. Our experienced team is ready to assist you with scheduling, sample collection, and result interpretation.

Book your CEBPA Full Gene Mutation Analysis today by calling +1(267) 388-9828 or visiting our nearest testing center. Take the first step toward comprehensive genetic understanding and personalized healthcare planning.